Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma-Reference-Cited by-同舟云学术

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma

Published:2019-03-18 Issue:4 Volume:21 Page:537-546
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Kieran Mark W¹,Goumnerova Liliana¹²,Manley Peter¹,Chi Susan N¹,Marcus Karen J¹³,Manzanera Andrea G⁴⁵,Polanco Maria Lucia Silva⁴⁵,Guzik Brian W⁴⁵,Aguilar-Cordova Estuardo⁴⁵,Diaz-Montero C Marcela⁶,DiPatri Arthur J⁷,Tomita Tadanori⁷,Lulla Rishi⁷,Greenspan Lianne¹,Aguilar Laura K⁴⁵,Goldman Stewart⁷

Affiliation:

1. Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Pediatric Hematology/Oncology, Boston Children’s Hospital

2. Department of Neurosurgery, Boston Children’s Hospital

3. Department of Radiation Therapy, Dana-Farber Cancer Institute

4. Harvard Medical School, Boston, Massachusetts

5. Advantagene, Inc, Auburndale, Massachusetts

6. Department of Immunology, Cleveland Clinic, Cleveland, Ohio

7. Division of Hematology/Oncology, Ann & Robert H. Lurie Children’s Hospital of Chicago and Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Funder

Matthew Larson Foundation

Joe Andruzzi Foundation

CJ Buckley Brain Cancer Research Fund

Zach Carson Fund

Ellie Kavalieros DIPG Fund

Advantagene, Inc

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link